Glenmark Pharmaceuticals Ltd. News and Updates

Keep track of all breaking news on Glenmark Pharmaceuticals Ltd. from all sources in a single place.

30 Mar 2025

1381.90

0.28%

Spurious batch of Telma H flagged, 103 other drugs fail CDSCO tests

Business Standard

Telma H is manufactured by Glenmark Pharmaceuticals and is prescribed for controlling high blood pressure, particularly in individuals prone to water retention or heart failure

Glenmark Pharmaceuticals Ltd. has gained 31.38% in the last 1 Year

Glenmark Pharmaceuticals Ltd.

21 Mar 2025

1381.90

0.28%

Glenmark Pharma share rises 2% on securing USFDA nod; key details here

Business Standard

Glenmark Pharma's stock rose after it said Glenmark Pharmaceuticals Inc., USA, has received final approval from the USFDA for its Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%

Glenmark Pharmaceuticals Ltd. has lost -23.99% in the last 6 Months

Glenmark Pharmaceuticals Ltd.

12 Mar 2025

1381.90

0.28%

Glenmark launches Empagliflozin for diabetes in India under Glempa brand

Business Standard

Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes patients. The Mumbai-based drug firm has launched Empagliflozin, a widely recognised SGLT2 inhibitor, under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)'?Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg). The medications are designed to improve glycemic control in adults with type 2 diabetes mellitus while also reducing cardiovascular outcomes in patients with cardiovascular risk. Studies have demonstrated several benefits of Empagliflozin, including effectively improving glycemic control, supporting weight-loss, and reducing cardiovascular-renal risks in patients with type 2 diabetes mellitus. Empagliflozin has also demonstrated benefits in heart failure patients by lowering the cardiovascular death or hospitalisation. "The launch of Glempa range ..

Glenmark Pharmaceuti.. has an average target of 1702.25 from 5 brokers.

Glenmark Pharmaceuticals Ltd.

02 Mar 2025

1381.90

0.28%

Glenmark Pharma Recalls 15 Lakh Bottles Of ADHD Medication In US: FDA

NDTV Profit

The recall is due to the 'presence of N-Nitroso Atomoxetine impurity above the FDA-recommended limit'.

Glenmark Pharmaceuticals Ltd. has gained 31.38% in the last 1 Year

Glenmark recalls 1.5 million bottles of ADHD medication in US: USFDA

Business Standard | 02 Mar 2025

Glenmark Pharmaceuticals Ltd.

27 Feb 2025

1381.90

0.28%

Glenmark Pharma Launches Epinephrine Injection In US

NDTV Profit

The injection is used to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock and also for emergency treatment of allergic reactions.

Glenmark Pharmaceuticals Ltd. has lost -23.99% in the last 6 Months

Glenmark Pharmaceuticals Ltd.

17 Feb 2025

1381.90

0.28%

Glenmark Pharmaceuticals share price gains 5% post Q3 Results: Do you own it?

livemint

Stock Market Today: Glenmark Pharmaceuticals share price gained more than 5% during intraday trades on Monday post Q3 Results that were declared after the market Hours. Do you own it?

Number of FII/FPI investors increased from 396 to 402 in Dec 2024 qtr.

Glenmark Pharma Share Price Rises After India Sales Grow 300% In Q3

NDTV Profit | 17 Feb 2025

Glenmark Pharmaceuticals Ltd.

17 Feb 2025

1381.90

0.28%

Glenmark Pharmaceuticals Results Earnings Call for Q3FY25

Conference Call with Glenmark Pharmaceuticals Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.

Glenmark Pharmaceuticals Ltd.

14 Feb 2025, 08:45PM

1381.90

0.28%

Glenmark Pharma clocks Q3 PAT of 348 crore

Business Line

The company clocked profit after tax (PAT) for the quarter ended December 31, 2024 at Rs 348 crore

Number of FII/FPI investors increased from 396 to 402 in Dec 2024 qtr.

Glenmark Pharma Q3 results: Net profit down at Rs 348 cr on weak US sales

Business Standard | 14 Feb 2025, 07:57PM 1 more

Glenmark Pharmaceuticals Ltd.

21 Jan 2025

1381.90

0.28%

Glenmark Pharma's US arm launches drug to treat blood clotting issues

Business Standard

According to IQVIA data for the 12-month period ending November 2024, the Vitamin K1 injectable emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million in the US